Jagpreet Grewal, Neeta Tripathi, Ben Bortner, Mathew J Gregoski, Daniel Cook, Annie Britt, R N Jennifer Hajj, Michael Rofael, Mariyam Sheidu, Margaret J Montovano, Mili Mehta, Alexander G Hajduczok, Indranee N Rajapreyar, Yevgeniy Brailovsky, Michael V Genuardi, Manreet K Kanwar, Pavan Atluri, Matthew Lander, Palak Shah, Steven Hsu, Arman Kilic, Brian A Houston, Mandeep R Mehra, Farooq Sheikh, Ryan J Tedford
BACKGROUND: The Heartmate 3 (HM3) risk score (HM3RS) was derived and validated internally from within the MOMENTUM 3 trial population and provides 1- and 2-year mortality risk prediction for patients in those prior to HM3 left ventricular assist device (LVAD) implantation. We aimed to evaluate the HM3RS in non-trial unselected patients, including those not meeting inclusion criteria for MOMENTUM 3 trial enrollment. METHODS: Patients who underwent HM3 LVAD implant at one of 7 US centers between 2017-2021, with at least 1 year follow up, were included in this analysis...
December 5, 2023: Journal of Heart and Lung Transplantation